Please try another search
Investing.com - Alnylam (NASDAQ: ALNY) reported third quarter EPS of $1.74, $3.06 better than the analyst estimate of $-1.32. Revenue for the quarter came in at $750.5M versus the consensus estimate...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from the APOLLO-B Phase 3 study of investigational patisiran in patients with the...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi...
Cambridge, Massachusetts-based Amylyx Pharmaceuticals has encountered a regulatory obstacle in Europe for its ALS treatment, AMX0035, also known as Albrioza or Relyvrio. The European Medicines Agency...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review